Good evening :)
Place Order
Add to Watchlist

Acutaas Chemicals Ltd

ACUTAAS Share Price

1,097.603.06% (-34.60)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

ACUTAAS Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

ACUTAAS Performance & Key Metrics

ACUTAAS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
56.6213.160.12%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.496.520.85%

ACUTAAS Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 5 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

ACUTAAS Company Profile

Acutaas Chemicals Limited specializes in manufacturing pharmaceutical intermediates and specialty chemicals for various industries, including pharmaceuticals and agrochemicals, with over 520 products developed across multiple therapeutic areas.

Investor Presentation

View older View older 

May 2, 2025

PDF
View Older Presentations

ACUTAAS Similar Stocks (Peers)

Compare with peers Compare with peers 

ACUTAAS Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
46.38
46.38
1Y Return
2.92%
2.92%
Buy Reco %
73.33
73.33
PE Ratio
-1,241.22
-1,241.22
1Y Return
13.89%
13.89%
Buy Reco %
100.00
100.00
PE Ratio
92.42
92.42
1Y Return
1.37%
1.37%
Buy Reco %
66.67
66.67
PE Ratio
-303.73
-303.73
1Y Return
211.37%
211.37%
Buy Reco %
0.00
0.00
PE Ratio
54.42
54.42
1Y Return
32.19%
32.19%
Buy Reco %
0.00
0.00
Compare with Peers

ACUTAAS Sentiment Analysis

ACUTAAS Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

ACUTAAS Stock Summary · May 2025

The company has achieved a remarkable milestone by surpassing INR 1,000 crore in revenue for FY '25, driven by strong performance in its pharmaceutical intermediates and a robust CDMO pipeline. Management anticipates a 25% revenue growth for FY '26, bolstered by new contracts and expanding operations in Japan, despite facing challenges in the Specialty Chemicals segment and sluggish demand in certain areas. With zero debt and a commitment to maintaining a strong financial position, the company is investing INR 200 crores in capital expenditures to enhance production capabilities. While navigating macroeconomic risks, particularly related to tariffs, the focus on long-term supply contracts and operational efficiency positions the company favorably for future growth.

ACUTAAS Stock Growth Drivers
ACUTAAS Stock Growth Drivers
9
  • Significant Revenue Milestone

    Ami Organics has achieved a significant milestone by surpassing the INR1,000 crore revenue threshold in

  • Strategic Positioning in Pharmaceuticals

    The company is strategically positioned to benefit from India's growing recognition as an alternative to

ACUTAAS Stock Challenges
ACUTAAS Stock Challenges
2
  • Stagnation in Specialty Chemicals Segment

    The Specialty Chemicals segment reported flat revenue of INR 36 crores in Q4 FY '25,

  • Seasonal Revenue Weakness

    The company highlighted that Q1 is typically their weakest quarter, with revenue expected to increase

end marker

ACUTAAS Forecast

ACUTAAS Forecasts

Price

Revenue

Earnings

ACUTAAS

ACUTAAS

Income

Balance Sheet

Cash Flow

ACUTAAS Income Statement

ACUTAAS Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 24.86%, vs industry avg of 19.23%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 3.03% to 3.78%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 12.91%, vs industry avg of 2.33%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue160.47191.18238.89242.48341.99522.90621.05724.961,023.801,023.80
Raw Materialssubtract94.75114.72151.95137.96174.87282.33345.85440.17774.80774.80
Power & Fuel Costsubtract1.001.274.144.545.2621.4022.2825.82
Employee Costsubtract7.389.898.5412.9521.0141.3748.8463.11
Selling & Administrative Expensessubtract17.6012.5614.7715.3812.1327.3436.6933.12
Operating & Other expensessubtract16.4019.2617.0327.7947.1842.5140.4658.85
Depreciation/Amortizationsubtract1.371.912.603.524.1910.0812.3416.0626.6226.63
Interest & Other Itemssubtract3.303.234.755.595.626.412.415.946.226.22
Taxes & Other Itemssubtract6.639.8611.817.2917.7219.5028.8839.1457.4557.44
EPS1.912.933.704.368.5710.5911.435.839.9121.52
DPS0.000.000.000.000.001.501.501.501.501.50
Payout ratio0.000.000.000.000.000.140.130.260.150.07

ACUTAAS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 2PDF
Jan 28PDF
Oct 29PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 14PDF
Feb 4PDF
Nov 5PDF
+2 more
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 16PDF
 

ACUTAAS Stock Peers

ACUTAAS Past Performance & Peer Comparison

ACUTAAS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Acutaas Chemicals Ltd56.6213.160.12%
Biocon Ltd46.381.860.32%
Onesource Specialty Pharma Ltd-1,241.2256.33
Sai Life Sciences Ltd92.4216.12

ACUTAAS Stock Price Comparison

Compare ACUTAAS with any stock or ETF
Compare ACUTAAS with any stock or ETF
ACUTAAS
Loading...

ACUTAAS Holdings

ACUTAAS Shareholdings

ACUTAAS Promoter Holdings Trend

ACUTAAS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

ACUTAAS Institutional Holdings Trend

ACUTAAS Institutional Holdings Trend

Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.07%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

ACUTAAS Shareholding Pattern

ACUTAAS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding35.96%13.02%5.30%16.48%29.25%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

ACUTAAS Shareholding History

ACUTAAS Shareholding History

MarMayJunSepDec '24Mar8.97%10.01%12.92%13.87%15.52%16.48%

Mutual Funds Invested in ACUTAAS

Mutual Funds Invested in ACUTAAS

No mutual funds holding trends are available

Top 5 Mutual Funds holding Acutaas Chemicals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
3.0154%0.87%-0.05%42/88 (-1)
1.7722%0.90%0.90%47/79 (+24)
1.2972%3.19%-0.08%11/32 (+2)

Compare 3-month MF holding change on Screener

ACUTAAS Insider Trades & Bulk Stock Deals

ACUTAAS Insider Trades & Bulk Stock Deals

Loading...

smallcases containing ACUTAAS stock

smallcases containing ACUTAAS stock

Looks like this stock is not in any smallcase yet.

ACUTAAS Events

ACUTAAS Events

ACUTAAS Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

ACUTAAS Dividend Trend

No dividend trend available

ACUTAAS Upcoming Dividends

ACUTAAS Upcoming Dividends

No upcoming dividends are available

ACUTAAS Past Dividends

ACUTAAS Past Dividends

Cash Dividend

Ex DateEx DateSep 13, 2024

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 13, 2024

Cash Dividend

Ex DateEx DateSep 18, 2023

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 18, 2023

Cash Dividend

Ex DateEx DateJul 29, 2022

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Jul 29, 2022

ACUTAAS Stock News & Opinions

ACUTAAS Stock News & Opinions

Spotlight
Ami Organics jumps after Q4 PAT soars to Rs 627 cr

Revenue from operations jumped 37.13% year on year to Rs 308.48 crore during the quarter ended 31st March 2025. Profit before tax (PBT) soared 122.66% to Rs 82.83 crore in Q4 FY25 as compared with Rs 37.20 crore in Q4 FY24. EBITDA stood at Rs 85 crore, registering the growth of 96.8% as compared with Rs 432 crore in Q4 FY24. EBITDA margin was at 27.5% in Q4 FY25 as against 19.2% in Q4 FY24. In Q4 FY25, export stood at 74% and domestic business was at 26%. Naresh Patel, executive chairman & managing director, Ami Organics, said, 'I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed Rs 1,000 crore in revenue'a remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions. Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth.' Meanwhile, the company's board recommended of final dividend of Rs 1.5 per equity share for FY25 Ami Organics headquartered at Surat, is a research and development (R&D) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and chemicals for New Chemical Entities (NCE), and other specialty chemicals.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Ami Organics consolidated net profit rises 148.43% in the March 2025 quarter

Net profit of Ami Organics rose 148.43% to Rs 62.48 crore in the quarter ended March 2025 as against Rs 25.15 crore during the previous quarter ended March 2024. Sales rose 37.13% to Rs 308.48 crore in the quarter ended March 2025 as against Rs 224.96 crore during the previous quarter ended March 2024. For the full year,net profit rose 271.08% to Rs 158.71 crore in the year ended March 2025 as against Rs 42.77 crore during the previous year ended March 2024. Sales rose 40.34% to Rs 1006.88 crore in the year ended March 2025 as against Rs 717.47 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales308.48224.96 37 1006.88717.47 40 OPM %27.5419.19 -23.0517.91 - PBDT90.1342.43 112 242.78130.04 87 PBT82.8337.53 121 216.16113.98 90 NP62.4825.15 148 158.7142.77 271 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of AMI Organics recommends final dividend

AMI Organics announced that the Board of Directors of the Company at its meeting held on 2 May 2025, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 30%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
AMI Organics to hold board meeting

AMI Organics will hold a meeting of the Board of Directors of the Company on 2 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Ami Organics' Unit II receives Japan PMDA nod for GMP compliance

Ami Organics' manufacturing facility, Unit II situated at Ankleshwar, which is involved in manufacturing of various intermediates for Active Pharmaceuticals Ingredients, has received Good Manufacturing Practices (GMP) by Pharmaceutical and Medical Devices Agency, Japan (PMDA). Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
AMI Organics to hold EGM

AMI Organics announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 May 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Board of Ami Organics approves change in company name to Acutaas Chemicals

The Board of Ami Organics at its meeting held on 16 April 2025 has approved the change in the name of the Company from 'Ami Organics' to 'Acutaas Chemicals', and the consequential alteration the Memorandum of Association and Articles of Association to give effect to the same. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Ami Organics commissions 10.8 MW DC solar power plant

Ami Organics announced the full commissioning of its 10.8 MW DC solar power plant. The solar facility, located at Pratapnagar, Nandod, Narmada District, Gujarat, India, comprises two captive solar plants, each with a capacity of 5.4 MW. Speaking on this significant achievement, Naresh Patel, Chairman and Managing Director of Ami Organics Limited, stated: 'The successful commissioning of our 10.8MW solar power plant marks a crucial step in our journey towards a greener and more sustainable future. This project not only strengthens our commitment to environmental responsibility but also enhances our operational efficiency and cost-effectiveness. With our continued investment in renewable energy, we aim to make substantial progress in reducing our dependence on conventional power sources and moving towards a cleaner, and more sustainable energy portfolio.'Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
AMI Organics announces board meeting date

AMI Organics will hold a meeting of the Board of Directors of the Company on 21 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Board of Ami Organics to consider stock split

The Board of Ami Organics will meet on 21 February 2025 to consider the proposal for alteration in the share capital of the Company by way of sub-division / split of the existing equity shares of the face value Rs 10/- each. Powered by Capital Market - Live

4 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Acutaas Chemicals Ltd (ACUTAAS) today?

    The share price of ACUTAAS as on 23rd June 2025 is ₹1097.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Acutaas Chemicals Ltd (ACUTAAS) share?

    The past returns of Acutaas Chemicals Ltd (ACUTAAS) share are
    • Past 1 week: 2.10%
    • Past 1 month: -5.24%
    • Past 3 months: -9.42%
    • Past 6 months: 2.72%
    • Past 1 year: 64.77%
    • Past 3 years: 154.59%
    • Past 5 years: 134.78%

  3. What are the peers or stocks similar to Acutaas Chemicals Ltd (ACUTAAS)?
  4. What is the dividend yield % of Acutaas Chemicals Ltd (ACUTAAS) share?

    The current dividend yield of Acutaas Chemicals Ltd (ACUTAAS) is 0.12.

  5. What is the market cap of Acutaas Chemicals Ltd (ACUTAAS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Acutaas Chemicals Ltd (ACUTAAS) is ₹8985.93 Cr as of 23rd June 2025.

  6. What is the 52 week high and low of Acutaas Chemicals Ltd (ACUTAAS) share?

    The 52-week high of Acutaas Chemicals Ltd (ACUTAAS) is ₹1322 and the 52-week low is ₹607.50.

  7. What is the PE and PB ratio of Acutaas Chemicals Ltd (ACUTAAS) stock?

    The P/E (price-to-earnings) ratio of Acutaas Chemicals Ltd (ACUTAAS) is 56.62. The P/B (price-to-book) ratio is 13.16.

  8. Which sector does Acutaas Chemicals Ltd (ACUTAAS) belong to?

    Acutaas Chemicals Ltd (ACUTAAS) belongs to the Health Care sector & Biotechnology sub-sector.

  9. How to buy Acutaas Chemicals Ltd (ACUTAAS) shares?

    You can directly buy Acutaas Chemicals Ltd (ACUTAAS) shares on Tickertape. Simply sign up, connect your demat account and place your order.